PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.
Identifieur interne : 003655 ( Main/Exploration ); précédent : 003654; suivant : 003656PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.
Auteurs : Martin Weisser [Allemagne] ; Ru-Fang Yeh [États-Unis] ; Guillemette Duchateau-Nguyen [Suisse] ; Giuseppe Palermo [Suisse] ; Tri Quang Nguyen [Suisse] ; Xiaoyan Shi [États-Unis] ; Susanna Y. Stinson [États-Unis] ; Nancy Yu [États-Unis] ; Annika Dufour [Allemagne] ; Tadeusz Robak [Pologne] ; Galina N. Salogub [Russie] ; Anna Dmoszynska [Pologne] ; Philippe Solal-Celigny [France] ; Krzysztof Warzocha [Pologne] ; Javier Loscertales [Espagne] ; John Catalano [Australie] ; Loree Larratt [Canada] ; Viktor A. Rossiev [Russie] ; Isabelle Bence-Bruckler [Canada] ; Christian H. Geisler [Danemark] ; Marco Montillo [Italie] ; Kirsten Fischer [Allemagne] ; Anna-Maria Fink [Allemagne] ; Michael Hallek [Allemagne] ; Johannes Bloehdorn [Allemagne] ; Raymonde Busch [Allemagne] ; Axel Benner [Allemagne] ; Hartmut Döhner [Allemagne] ; Nancy Valente ; Michael K. Wenger [Suisse] ; Stephan Stilgenbauer [Allemagne] ; David Dornan [États-Unis]Source :
- Blood [ 1528-0020 ] ; 2014.
Descripteurs français
- KwdFr :
- ARN messager (génétique), ARN messager (métabolisme), ARN tumoral (génétique), ARN tumoral (métabolisme), Anticorps monoclonaux d'origine murine (administration et posologie), Association thérapeutique, Cyclophosphamide (administration et posologie), Expression des gènes, Focal adhesion kinase 1 (génétique), Humains, Immunothérapie, Leucémie chronique lymphocytaire à cellules B (), Leucémie chronique lymphocytaire à cellules B (enzymologie), Leucémie chronique lymphocytaire à cellules B (génétique), Modèles de hasards proportionnels, Protocoles de polychimiothérapie antinéoplasique (administration et posologie), Rituximab, Récidive, Survie sans rechute, Vidarabine (administration et posologie), Vidarabine (analogues et dérivés), Études rétrospectives.
- MESH :
- administration et posologie : Anticorps monoclonaux d'origine murine, Cyclophosphamide, Protocoles de polychimiothérapie antinéoplasique, Vidarabine.
- analogues et dérivés : Vidarabine.
- enzymologie : Leucémie chronique lymphocytaire à cellules B.
- génétique : ARN messager, ARN tumoral, Focal adhesion kinase 1, Leucémie chronique lymphocytaire à cellules B.
- métabolisme : ARN messager, ARN tumoral.
- Association thérapeutique, Expression des gènes, Humains, Immunothérapie, Leucémie chronique lymphocytaire à cellules B, Modèles de hasards proportionnels, Rituximab, Récidive, Survie sans rechute, Études rétrospectives.
English descriptors
- KwdEn :
- Antibodies, Monoclonal, Murine-Derived (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Combined Modality Therapy, Cyclophosphamide (administration & dosage), Disease-Free Survival, Focal Adhesion Kinase 1 (genetics), Gene Expression, Humans, Immunotherapy, Leukemia, Lymphocytic, Chronic, B-Cell (enzymology), Leukemia, Lymphocytic, Chronic, B-Cell (genetics), Leukemia, Lymphocytic, Chronic, B-Cell (therapy), Proportional Hazards Models, RNA, Messenger (genetics), RNA, Messenger (metabolism), RNA, Neoplasm (genetics), RNA, Neoplasm (metabolism), Recurrence, Retrospective Studies, Rituximab, Vidarabine (administration & dosage), Vidarabine (analogs & derivatives).
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Murine-Derived, Cyclophosphamide, Vidarabine.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- chemical , analogs & derivatives : Vidarabine.
- enzymology : Leukemia, Lymphocytic, Chronic, B-Cell.
- chemical , genetics : Focal Adhesion Kinase 1, Leukemia, Lymphocytic, Chronic, B-Cell, RNA, Messenger, RNA, Neoplasm.
- chemical , metabolism : RNA, Messenger, RNA, Neoplasm.
- therapy : Leukemia, Lymphocytic, Chronic, B-Cell.
- Combined Modality Therapy, Disease-Free Survival, Gene Expression, Humans, Immunotherapy, Proportional Hazards Models, Recurrence, Retrospective Studies, Rituximab.
Abstract
Addition of rituximab (R) to fludarabine and cyclophosphamide (FC) has significantly improved patient outcomes in chronic lymphocytic leukemia (CLL). Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined. We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH, a study of FC or R-FC in relapsed CLL. An independent test set was derived from 282 pretreatment specimens from CLL8, a study of FC or R-FC in treatment-naïve patients. Genes specific for benefit from R-FC were determined by assessing treatment-gene interactions in Cox proportional hazards models. REACH patients with higher pretreatment protein tyrosine kinase 2 (PTK2) messenger RNA levels derived greater benefit from R-FC, with significant improvements in progression-free survival, independent of known prognostic factors in a multivariate model. Examination of PTK2 gene expression in CLL8 patients yielded similar results. Furthermore, PTK2 inhibition blunted R-dependent cell death in vitro. This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC. PTK2 expression may be a useful biomarker for patient selection in future trials. These trials were registered at www.clinicaltrials.gov as #NCT00090051 (REACH) and #NCT00281918 (CLL8).
DOI: 10.1182/blood-2013-12-538975
PubMed: 24916506
Affiliations:
- Allemagne, Australie, Canada, Danemark, Espagne, France, Italie, Pologne, Russie, Suisse, États-Unis
- Bade-Wurtemberg, Bavière, Californie, Communauté de Madrid, District de Haute-Bavière, District de Karlsruhe, District de Tübingen, Hovedstaden, Lombardie, Pays de la Loire
- Copenhague, Heidelberg, Madrid, Milan, Munich, Nantes, Ulm
- Université Louis-et-Maximilien de Munich, Université d'Ulm
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003663
- to stream PubMed, to step Curation: 003550
- to stream PubMed, to step Checkpoint: 003550
- to stream Ncbi, to step Merge: 001B06
- to stream Ncbi, to step Curation: 001B06
- to stream Ncbi, to step Checkpoint: 001B06
- to stream Main, to step Merge: 003677
- to stream Main, to step Curation: 003655
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.</title><author><name sortKey="Weisser, Martin" sort="Weisser, Martin" uniqKey="Weisser M" first="Martin" last="Weisser">Martin Weisser</name><affiliation wicri:level="1"><nlm:affiliation>Roche Pharma Research and Early Development, Penzberg, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Roche Pharma Research and Early Development, Penzberg</wicri:regionArea><wicri:noRegion>Penzberg</wicri:noRegion><wicri:noRegion>Penzberg</wicri:noRegion><wicri:noRegion>Penzberg</wicri:noRegion></affiliation></author><author><name sortKey="Yeh, Ru Fang" sort="Yeh, Ru Fang" uniqKey="Yeh R" first="Ru-Fang" last="Yeh">Ru-Fang Yeh</name><affiliation wicri:level="2"><nlm:affiliation>Biostatistics, Genentech Inc., South San Francisco, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Biostatistics, Genentech Inc., South San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Duchateau Nguyen, Guillemette" sort="Duchateau Nguyen, Guillemette" uniqKey="Duchateau Nguyen G" first="Guillemette" last="Duchateau-Nguyen">Guillemette Duchateau-Nguyen</name><affiliation wicri:level="1"><nlm:affiliation>F. Hoffman-La Roche Ltd., Basel, Switzerland;</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>F. Hoffman-La Roche Ltd., Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Palermo, Giuseppe" sort="Palermo, Giuseppe" uniqKey="Palermo G" first="Giuseppe" last="Palermo">Giuseppe Palermo</name><affiliation wicri:level="1"><nlm:affiliation>F. Hoffman-La Roche Ltd., Basel, Switzerland;</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>F. Hoffman-La Roche Ltd., Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Nguyen, Tri Quang" sort="Nguyen, Tri Quang" uniqKey="Nguyen T" first="Tri Quang" last="Nguyen">Tri Quang Nguyen</name><affiliation wicri:level="1"><nlm:affiliation>F. Hoffman-La Roche Ltd., Basel, Switzerland;</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>F. Hoffman-La Roche Ltd., Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Shi, Xiaoyan" sort="Shi, Xiaoyan" uniqKey="Shi X" first="Xiaoyan" last="Shi">Xiaoyan Shi</name><affiliation wicri:level="2"><nlm:affiliation>Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Stinson, Susanna Y" sort="Stinson, Susanna Y" uniqKey="Stinson S" first="Susanna Y" last="Stinson">Susanna Y. Stinson</name><affiliation wicri:level="2"><nlm:affiliation>Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Yu, Nancy" sort="Yu, Nancy" uniqKey="Yu N" first="Nancy" last="Yu">Nancy Yu</name><affiliation wicri:level="2"><nlm:affiliation>Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Dufour, Annika" sort="Dufour, Annika" uniqKey="Dufour A" first="Annika" last="Dufour">Annika Dufour</name><affiliation wicri:level="4"><nlm:affiliation>Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, Munich, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement><settlement type="city">Munich</settlement></placeName><orgName type="university">Université Louis-et-Maximilien de Munich</orgName></affiliation></author><author><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Medical University, Lodz, Poland;</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Haematology, Medical University, Lodz</wicri:regionArea><wicri:noRegion>Lodz</wicri:noRegion></affiliation></author><author><name sortKey="Salogub, Galina N" sort="Salogub, Galina N" uniqKey="Salogub G" first="Galina N" last="Salogub">Galina N. Salogub</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Saint Petersburg Pavlov State Medical University, Saint Petersburg, Russia;</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Hematology Department, Saint Petersburg Pavlov State Medical University, Saint Petersburg</wicri:regionArea><wicri:noRegion>Saint Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Dmoszynska, Anna" sort="Dmoszynska, Anna" uniqKey="Dmoszynska A" first="Anna" last="Dmoszynska">Anna Dmoszynska</name><affiliation wicri:level="1"><nlm:affiliation>Haematooncology and Bone Marrow Transplantation Department, Medical University, Lublin, Poland;</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Haematooncology and Bone Marrow Transplantation Department, Medical University, Lublin</wicri:regionArea><wicri:noRegion>Lublin</wicri:noRegion></affiliation></author><author><name sortKey="Solal Celigny, Philippe" sort="Solal Celigny, Philippe" uniqKey="Solal Celigny P" first="Philippe" last="Solal-Celigny">Philippe Solal-Celigny</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hematology, Institut de Cancérologie de l'Ouest, Nantes, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Hematology, Institut de Cancérologie de l'Ouest, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Warzocha, Krzysztof" sort="Warzocha, Krzysztof" uniqKey="Warzocha K" first="Krzysztof" last="Warzocha">Krzysztof Warzocha</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Loscertales, Javier" sort="Loscertales, Javier" uniqKey="Loscertales J" first="Javier" last="Loscertales">Javier Loscertales</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hematology, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain;</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Hematology, Hospital Universitario de La Princesa, IIS-IP, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Catalano, John" sort="Catalano, John" uniqKey="Catalano J" first="John" last="Catalano">John Catalano</name><affiliation wicri:level="1"><nlm:affiliation>Dorevitch Pathology Laboratory, Frankston Hospital, Frankston, Australia;</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Dorevitch Pathology Laboratory, Frankston Hospital, Frankston</wicri:regionArea><wicri:noRegion>Frankston</wicri:noRegion></affiliation></author><author><name sortKey="Larratt, Loree" sort="Larratt, Loree" uniqKey="Larratt L" first="Loree" last="Larratt">Loree Larratt</name><affiliation wicri:level="1"><nlm:affiliation>Division of Clinical Hematology, Walter C. Mackenzie Health Sciences Centre, Edmonton, AB, Canada;</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Clinical Hematology, Walter C. Mackenzie Health Sciences Centre, Edmonton, AB</wicri:regionArea><wicri:noRegion>AB</wicri:noRegion></affiliation></author><author><name sortKey="Rossiev, Viktor A" sort="Rossiev, Viktor A" uniqKey="Rossiev V" first="Viktor A" last="Rossiev">Viktor A. Rossiev</name><affiliation wicri:level="1"><nlm:affiliation>Haematology Department, Samara Region Clinical Hospital, Samara, Russia;</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Haematology Department, Samara Region Clinical Hospital, Samara</wicri:regionArea><wicri:noRegion>Samara</wicri:noRegion></affiliation></author><author><name sortKey="Bence Bruckler, Isabelle" sort="Bence Bruckler, Isabelle" uniqKey="Bence Bruckler I" first="Isabelle" last="Bence-Bruckler">Isabelle Bence-Bruckler</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada;</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Geisler, Christian H" sort="Geisler, Christian H" uniqKey="Geisler C" first="Christian H" last="Geisler">Christian H. Geisler</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hematology, Rigshospitalet, Copenhagen, Denmark;</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Hematology, Rigshospitalet, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Montillo, Marco" sort="Montillo, Marco" uniqKey="Montillo M" first="Marco" last="Montillo">Marco Montillo</name><affiliation wicri:level="3"><nlm:affiliation>Department of Haematology & Oncology, Division of Haematology, Ospedale Niguarda Ca' Granda, Milan, Italy;</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Haematology & Oncology, Division of Haematology, Ospedale Niguarda Ca' Granda, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Fischer, Kirsten" sort="Fischer, Kirsten" uniqKey="Fischer K" first="Kirsten" last="Fischer">Kirsten Fischer</name><affiliation wicri:level="1"><nlm:affiliation>Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne</wicri:regionArea><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Fink, Anna Maria" sort="Fink, Anna Maria" uniqKey="Fink A" first="Anna-Maria" last="Fink">Anna-Maria Fink</name><affiliation wicri:level="1"><nlm:affiliation>Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne</wicri:regionArea><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Hallek, Michael" sort="Hallek, Michael" uniqKey="Hallek M" first="Michael" last="Hallek">Michael Hallek</name><affiliation wicri:level="1"><nlm:affiliation>Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne</wicri:regionArea><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Bloehdorn, Johannes" sort="Bloehdorn, Johannes" uniqKey="Bloehdorn J" first="Johannes" last="Bloehdorn">Johannes Bloehdorn</name><affiliation wicri:level="4"><nlm:affiliation>Department of Internal Medicine III, University of Ulm, Ulm, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine III, University of Ulm, Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement><settlement type="city">Ulm</settlement></placeName><orgName type="university">Université d'Ulm</orgName></affiliation></author><author><name sortKey="Busch, Raymonde" sort="Busch, Raymonde" uniqKey="Busch R" first="Raymonde" last="Busch">Raymonde Busch</name><affiliation wicri:level="4"><nlm:affiliation>Institute for Medical Statistics and Epidemiology, Technical University of Munich, Munich, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Medical Statistics and Epidemiology, Technical University of Munich, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement><settlement type="city">Munich</settlement></placeName><orgName type="university">Université Louis-et-Maximilien de Munich</orgName></affiliation></author><author><name sortKey="Benner, Axel" sort="Benner, Axel" uniqKey="Benner A" first="Axel" last="Benner">Axel Benner</name><affiliation wicri:level="3"><nlm:affiliation>Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Division of Biostatistics, German Cancer Research Center, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Dohner, Hartmut" sort="Dohner, Hartmut" uniqKey="Dohner H" first="Hartmut" last="Döhner">Hartmut Döhner</name><affiliation wicri:level="4"><nlm:affiliation>Department of Internal Medicine III, University of Ulm, Ulm, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine III, University of Ulm, Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement><settlement type="city">Ulm</settlement></placeName><orgName type="university">Université d'Ulm</orgName></affiliation></author><author><name sortKey="Valente, Nancy" sort="Valente, Nancy" uniqKey="Valente N" first="Nancy" last="Valente">Nancy Valente</name><affiliation><nlm:affiliation>BioOncology, Genentech Inc., South San Francisco, CA; and.</nlm:affiliation><wicri:noCountry code="subField">CA; and</wicri:noCountry></affiliation></author><author><name sortKey="Wenger, Michael K" sort="Wenger, Michael K" uniqKey="Wenger M" first="Michael K" last="Wenger">Michael K. Wenger</name><affiliation wicri:level="1"><nlm:affiliation>Pharmaceuticals Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Pharmaceuticals Division, F. Hoffmann-La Roche Ltd., Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Stilgenbauer, Stephan" sort="Stilgenbauer, Stephan" uniqKey="Stilgenbauer S" first="Stephan" last="Stilgenbauer">Stephan Stilgenbauer</name><affiliation wicri:level="4"><nlm:affiliation>Department of Internal Medicine III, University of Ulm, Ulm, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine III, University of Ulm, Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement><settlement type="city">Ulm</settlement></placeName><orgName type="university">Université d'Ulm</orgName></affiliation></author><author><name sortKey="Dornan, David" sort="Dornan, David" uniqKey="Dornan D" first="David" last="Dornan">David Dornan</name><affiliation wicri:level="2"><nlm:affiliation>Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24916506</idno><idno type="pmid">24916506</idno><idno type="doi">10.1182/blood-2013-12-538975</idno><idno type="wicri:Area/PubMed/Corpus">003663</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003663</idno><idno type="wicri:Area/PubMed/Curation">003550</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003550</idno><idno type="wicri:Area/PubMed/Checkpoint">003550</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003550</idno><idno type="wicri:Area/Ncbi/Merge">001B06</idno><idno type="wicri:Area/Ncbi/Curation">001B06</idno><idno type="wicri:Area/Ncbi/Checkpoint">001B06</idno><idno type="wicri:Area/Main/Merge">003677</idno><idno type="wicri:Area/Main/Curation">003655</idno><idno type="wicri:Area/Main/Exploration">003655</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.</title><author><name sortKey="Weisser, Martin" sort="Weisser, Martin" uniqKey="Weisser M" first="Martin" last="Weisser">Martin Weisser</name><affiliation wicri:level="1"><nlm:affiliation>Roche Pharma Research and Early Development, Penzberg, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Roche Pharma Research and Early Development, Penzberg</wicri:regionArea><wicri:noRegion>Penzberg</wicri:noRegion><wicri:noRegion>Penzberg</wicri:noRegion><wicri:noRegion>Penzberg</wicri:noRegion></affiliation></author><author><name sortKey="Yeh, Ru Fang" sort="Yeh, Ru Fang" uniqKey="Yeh R" first="Ru-Fang" last="Yeh">Ru-Fang Yeh</name><affiliation wicri:level="2"><nlm:affiliation>Biostatistics, Genentech Inc., South San Francisco, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Biostatistics, Genentech Inc., South San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Duchateau Nguyen, Guillemette" sort="Duchateau Nguyen, Guillemette" uniqKey="Duchateau Nguyen G" first="Guillemette" last="Duchateau-Nguyen">Guillemette Duchateau-Nguyen</name><affiliation wicri:level="1"><nlm:affiliation>F. Hoffman-La Roche Ltd., Basel, Switzerland;</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>F. Hoffman-La Roche Ltd., Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Palermo, Giuseppe" sort="Palermo, Giuseppe" uniqKey="Palermo G" first="Giuseppe" last="Palermo">Giuseppe Palermo</name><affiliation wicri:level="1"><nlm:affiliation>F. Hoffman-La Roche Ltd., Basel, Switzerland;</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>F. Hoffman-La Roche Ltd., Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Nguyen, Tri Quang" sort="Nguyen, Tri Quang" uniqKey="Nguyen T" first="Tri Quang" last="Nguyen">Tri Quang Nguyen</name><affiliation wicri:level="1"><nlm:affiliation>F. Hoffman-La Roche Ltd., Basel, Switzerland;</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>F. Hoffman-La Roche Ltd., Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Shi, Xiaoyan" sort="Shi, Xiaoyan" uniqKey="Shi X" first="Xiaoyan" last="Shi">Xiaoyan Shi</name><affiliation wicri:level="2"><nlm:affiliation>Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Stinson, Susanna Y" sort="Stinson, Susanna Y" uniqKey="Stinson S" first="Susanna Y" last="Stinson">Susanna Y. Stinson</name><affiliation wicri:level="2"><nlm:affiliation>Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Yu, Nancy" sort="Yu, Nancy" uniqKey="Yu N" first="Nancy" last="Yu">Nancy Yu</name><affiliation wicri:level="2"><nlm:affiliation>Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Dufour, Annika" sort="Dufour, Annika" uniqKey="Dufour A" first="Annika" last="Dufour">Annika Dufour</name><affiliation wicri:level="4"><nlm:affiliation>Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, Munich, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement><settlement type="city">Munich</settlement></placeName><orgName type="university">Université Louis-et-Maximilien de Munich</orgName></affiliation></author><author><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Medical University, Lodz, Poland;</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Haematology, Medical University, Lodz</wicri:regionArea><wicri:noRegion>Lodz</wicri:noRegion></affiliation></author><author><name sortKey="Salogub, Galina N" sort="Salogub, Galina N" uniqKey="Salogub G" first="Galina N" last="Salogub">Galina N. Salogub</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Saint Petersburg Pavlov State Medical University, Saint Petersburg, Russia;</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Hematology Department, Saint Petersburg Pavlov State Medical University, Saint Petersburg</wicri:regionArea><wicri:noRegion>Saint Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Dmoszynska, Anna" sort="Dmoszynska, Anna" uniqKey="Dmoszynska A" first="Anna" last="Dmoszynska">Anna Dmoszynska</name><affiliation wicri:level="1"><nlm:affiliation>Haematooncology and Bone Marrow Transplantation Department, Medical University, Lublin, Poland;</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Haematooncology and Bone Marrow Transplantation Department, Medical University, Lublin</wicri:regionArea><wicri:noRegion>Lublin</wicri:noRegion></affiliation></author><author><name sortKey="Solal Celigny, Philippe" sort="Solal Celigny, Philippe" uniqKey="Solal Celigny P" first="Philippe" last="Solal-Celigny">Philippe Solal-Celigny</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hematology, Institut de Cancérologie de l'Ouest, Nantes, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Hematology, Institut de Cancérologie de l'Ouest, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Warzocha, Krzysztof" sort="Warzocha, Krzysztof" uniqKey="Warzocha K" first="Krzysztof" last="Warzocha">Krzysztof Warzocha</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Loscertales, Javier" sort="Loscertales, Javier" uniqKey="Loscertales J" first="Javier" last="Loscertales">Javier Loscertales</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hematology, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain;</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Hematology, Hospital Universitario de La Princesa, IIS-IP, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Catalano, John" sort="Catalano, John" uniqKey="Catalano J" first="John" last="Catalano">John Catalano</name><affiliation wicri:level="1"><nlm:affiliation>Dorevitch Pathology Laboratory, Frankston Hospital, Frankston, Australia;</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Dorevitch Pathology Laboratory, Frankston Hospital, Frankston</wicri:regionArea><wicri:noRegion>Frankston</wicri:noRegion></affiliation></author><author><name sortKey="Larratt, Loree" sort="Larratt, Loree" uniqKey="Larratt L" first="Loree" last="Larratt">Loree Larratt</name><affiliation wicri:level="1"><nlm:affiliation>Division of Clinical Hematology, Walter C. Mackenzie Health Sciences Centre, Edmonton, AB, Canada;</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Clinical Hematology, Walter C. Mackenzie Health Sciences Centre, Edmonton, AB</wicri:regionArea><wicri:noRegion>AB</wicri:noRegion></affiliation></author><author><name sortKey="Rossiev, Viktor A" sort="Rossiev, Viktor A" uniqKey="Rossiev V" first="Viktor A" last="Rossiev">Viktor A. Rossiev</name><affiliation wicri:level="1"><nlm:affiliation>Haematology Department, Samara Region Clinical Hospital, Samara, Russia;</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Haematology Department, Samara Region Clinical Hospital, Samara</wicri:regionArea><wicri:noRegion>Samara</wicri:noRegion></affiliation></author><author><name sortKey="Bence Bruckler, Isabelle" sort="Bence Bruckler, Isabelle" uniqKey="Bence Bruckler I" first="Isabelle" last="Bence-Bruckler">Isabelle Bence-Bruckler</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada;</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Geisler, Christian H" sort="Geisler, Christian H" uniqKey="Geisler C" first="Christian H" last="Geisler">Christian H. Geisler</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hematology, Rigshospitalet, Copenhagen, Denmark;</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Hematology, Rigshospitalet, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Montillo, Marco" sort="Montillo, Marco" uniqKey="Montillo M" first="Marco" last="Montillo">Marco Montillo</name><affiliation wicri:level="3"><nlm:affiliation>Department of Haematology & Oncology, Division of Haematology, Ospedale Niguarda Ca' Granda, Milan, Italy;</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Haematology & Oncology, Division of Haematology, Ospedale Niguarda Ca' Granda, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Fischer, Kirsten" sort="Fischer, Kirsten" uniqKey="Fischer K" first="Kirsten" last="Fischer">Kirsten Fischer</name><affiliation wicri:level="1"><nlm:affiliation>Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne</wicri:regionArea><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Fink, Anna Maria" sort="Fink, Anna Maria" uniqKey="Fink A" first="Anna-Maria" last="Fink">Anna-Maria Fink</name><affiliation wicri:level="1"><nlm:affiliation>Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne</wicri:regionArea><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Hallek, Michael" sort="Hallek, Michael" uniqKey="Hallek M" first="Michael" last="Hallek">Michael Hallek</name><affiliation wicri:level="1"><nlm:affiliation>Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne</wicri:regionArea><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Bloehdorn, Johannes" sort="Bloehdorn, Johannes" uniqKey="Bloehdorn J" first="Johannes" last="Bloehdorn">Johannes Bloehdorn</name><affiliation wicri:level="4"><nlm:affiliation>Department of Internal Medicine III, University of Ulm, Ulm, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine III, University of Ulm, Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement><settlement type="city">Ulm</settlement></placeName><orgName type="university">Université d'Ulm</orgName></affiliation></author><author><name sortKey="Busch, Raymonde" sort="Busch, Raymonde" uniqKey="Busch R" first="Raymonde" last="Busch">Raymonde Busch</name><affiliation wicri:level="4"><nlm:affiliation>Institute for Medical Statistics and Epidemiology, Technical University of Munich, Munich, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Medical Statistics and Epidemiology, Technical University of Munich, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement><settlement type="city">Munich</settlement></placeName><orgName type="university">Université Louis-et-Maximilien de Munich</orgName></affiliation></author><author><name sortKey="Benner, Axel" sort="Benner, Axel" uniqKey="Benner A" first="Axel" last="Benner">Axel Benner</name><affiliation wicri:level="3"><nlm:affiliation>Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Division of Biostatistics, German Cancer Research Center, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Dohner, Hartmut" sort="Dohner, Hartmut" uniqKey="Dohner H" first="Hartmut" last="Döhner">Hartmut Döhner</name><affiliation wicri:level="4"><nlm:affiliation>Department of Internal Medicine III, University of Ulm, Ulm, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine III, University of Ulm, Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement><settlement type="city">Ulm</settlement></placeName><orgName type="university">Université d'Ulm</orgName></affiliation></author><author><name sortKey="Valente, Nancy" sort="Valente, Nancy" uniqKey="Valente N" first="Nancy" last="Valente">Nancy Valente</name><affiliation><nlm:affiliation>BioOncology, Genentech Inc., South San Francisco, CA; and.</nlm:affiliation><wicri:noCountry code="subField">CA; and</wicri:noCountry></affiliation></author><author><name sortKey="Wenger, Michael K" sort="Wenger, Michael K" uniqKey="Wenger M" first="Michael K" last="Wenger">Michael K. Wenger</name><affiliation wicri:level="1"><nlm:affiliation>Pharmaceuticals Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Pharmaceuticals Division, F. Hoffmann-La Roche Ltd., Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Stilgenbauer, Stephan" sort="Stilgenbauer, Stephan" uniqKey="Stilgenbauer S" first="Stephan" last="Stilgenbauer">Stephan Stilgenbauer</name><affiliation wicri:level="4"><nlm:affiliation>Department of Internal Medicine III, University of Ulm, Ulm, Germany;</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine III, University of Ulm, Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement><settlement type="city">Ulm</settlement></placeName><orgName type="university">Université d'Ulm</orgName></affiliation></author><author><name sortKey="Dornan, David" sort="Dornan, David" uniqKey="Dornan D" first="David" last="Dornan">David Dornan</name><affiliation wicri:level="2"><nlm:affiliation>Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco, CA;</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Molecular Diagnostics and Cancer Cell Biology, Genentech Inc., South San Francisco</wicri:cityArea></affiliation></author></analytic><series><title level="j">Blood</title><idno type="eISSN">1528-0020</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Murine-Derived (administration & dosage)</term><term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term><term>Combined Modality Therapy</term><term>Cyclophosphamide (administration & dosage)</term><term>Disease-Free Survival</term><term>Focal Adhesion Kinase 1 (genetics)</term><term>Gene Expression</term><term>Humans</term><term>Immunotherapy</term><term>Leukemia, Lymphocytic, Chronic, B-Cell (enzymology)</term><term>Leukemia, Lymphocytic, Chronic, B-Cell (genetics)</term><term>Leukemia, Lymphocytic, Chronic, B-Cell (therapy)</term><term>Proportional Hazards Models</term><term>RNA, Messenger (genetics)</term><term>RNA, Messenger (metabolism)</term><term>RNA, Neoplasm (genetics)</term><term>RNA, Neoplasm (metabolism)</term><term>Recurrence</term><term>Retrospective Studies</term><term>Rituximab</term><term>Vidarabine (administration & dosage)</term><term>Vidarabine (analogs & derivatives)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ARN messager (génétique)</term><term>ARN messager (métabolisme)</term><term>ARN tumoral (génétique)</term><term>ARN tumoral (métabolisme)</term><term>Anticorps monoclonaux d'origine murine (administration et posologie)</term><term>Association thérapeutique</term><term>Cyclophosphamide (administration et posologie)</term><term>Expression des gènes</term><term>Focal adhesion kinase 1 (génétique)</term><term>Humains</term><term>Immunothérapie</term><term>Leucémie chronique lymphocytaire à cellules B ()</term><term>Leucémie chronique lymphocytaire à cellules B (enzymologie)</term><term>Leucémie chronique lymphocytaire à cellules B (génétique)</term><term>Modèles de hasards proportionnels</term><term>Protocoles de polychimiothérapie antinéoplasique (administration et posologie)</term><term>Rituximab</term><term>Récidive</term><term>Survie sans rechute</term><term>Vidarabine (administration et posologie)</term><term>Vidarabine (analogues et dérivés)</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Murine-Derived</term><term>Cyclophosphamide</term><term>Vidarabine</term></keywords><keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux d'origine murine</term><term>Cyclophosphamide</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Vidarabine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Vidarabine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Vidarabine</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Leucémie chronique lymphocytaire à cellules B</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Focal Adhesion Kinase 1</term><term>Leukemia, Lymphocytic, Chronic, B-Cell</term><term>RNA, Messenger</term><term>RNA, Neoplasm</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN messager</term><term>ARN tumoral</term><term>Focal adhesion kinase 1</term><term>Leucémie chronique lymphocytaire à cellules B</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>RNA, Messenger</term><term>RNA, Neoplasm</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>ARN messager</term><term>ARN tumoral</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Combined Modality Therapy</term><term>Disease-Free Survival</term><term>Gene Expression</term><term>Humans</term><term>Immunotherapy</term><term>Proportional Hazards Models</term><term>Recurrence</term><term>Retrospective Studies</term><term>Rituximab</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Association thérapeutique</term><term>Expression des gènes</term><term>Humains</term><term>Immunothérapie</term><term>Leucémie chronique lymphocytaire à cellules B</term><term>Modèles de hasards proportionnels</term><term>Rituximab</term><term>Récidive</term><term>Survie sans rechute</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Addition of rituximab (R) to fludarabine and cyclophosphamide (FC) has significantly improved patient outcomes in chronic lymphocytic leukemia (CLL). Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined. We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH, a study of FC or R-FC in relapsed CLL. An independent test set was derived from 282 pretreatment specimens from CLL8, a study of FC or R-FC in treatment-naïve patients. Genes specific for benefit from R-FC were determined by assessing treatment-gene interactions in Cox proportional hazards models. REACH patients with higher pretreatment protein tyrosine kinase 2 (PTK2) messenger RNA levels derived greater benefit from R-FC, with significant improvements in progression-free survival, independent of known prognostic factors in a multivariate model. Examination of PTK2 gene expression in CLL8 patients yielded similar results. Furthermore, PTK2 inhibition blunted R-dependent cell death in vitro. This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC. PTK2 expression may be a useful biomarker for patient selection in future trials. These trials were registered at www.clinicaltrials.gov as #NCT00090051 (REACH) and #NCT00281918 (CLL8).</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>Danemark</li><li>Espagne</li><li>France</li><li>Italie</li><li>Pologne</li><li>Russie</li><li>Suisse</li><li>États-Unis</li></country><region><li>Bade-Wurtemberg</li><li>Bavière</li><li>Californie</li><li>Communauté de Madrid</li><li>District de Haute-Bavière</li><li>District de Karlsruhe</li><li>District de Tübingen</li><li>Hovedstaden</li><li>Lombardie</li><li>Pays de la Loire</li></region><settlement><li>Copenhague</li><li>Heidelberg</li><li>Madrid</li><li>Milan</li><li>Munich</li><li>Nantes</li><li>Ulm</li></settlement><orgName><li>Université Louis-et-Maximilien de Munich</li><li>Université d'Ulm</li></orgName></list><tree><noCountry><name sortKey="Valente, Nancy" sort="Valente, Nancy" uniqKey="Valente N" first="Nancy" last="Valente">Nancy Valente</name></noCountry><country name="Allemagne"><noRegion><name sortKey="Weisser, Martin" sort="Weisser, Martin" uniqKey="Weisser M" first="Martin" last="Weisser">Martin Weisser</name></noRegion><name sortKey="Benner, Axel" sort="Benner, Axel" uniqKey="Benner A" first="Axel" last="Benner">Axel Benner</name><name sortKey="Bloehdorn, Johannes" sort="Bloehdorn, Johannes" uniqKey="Bloehdorn J" first="Johannes" last="Bloehdorn">Johannes Bloehdorn</name><name sortKey="Busch, Raymonde" sort="Busch, Raymonde" uniqKey="Busch R" first="Raymonde" last="Busch">Raymonde Busch</name><name sortKey="Dohner, Hartmut" sort="Dohner, Hartmut" uniqKey="Dohner H" first="Hartmut" last="Döhner">Hartmut Döhner</name><name sortKey="Dufour, Annika" sort="Dufour, Annika" uniqKey="Dufour A" first="Annika" last="Dufour">Annika Dufour</name><name sortKey="Fink, Anna Maria" sort="Fink, Anna Maria" uniqKey="Fink A" first="Anna-Maria" last="Fink">Anna-Maria Fink</name><name sortKey="Fischer, Kirsten" sort="Fischer, Kirsten" uniqKey="Fischer K" first="Kirsten" last="Fischer">Kirsten Fischer</name><name sortKey="Hallek, Michael" sort="Hallek, Michael" uniqKey="Hallek M" first="Michael" last="Hallek">Michael Hallek</name><name sortKey="Stilgenbauer, Stephan" sort="Stilgenbauer, Stephan" uniqKey="Stilgenbauer S" first="Stephan" last="Stilgenbauer">Stephan Stilgenbauer</name></country><country name="États-Unis"><region name="Californie"><name sortKey="Yeh, Ru Fang" sort="Yeh, Ru Fang" uniqKey="Yeh R" first="Ru-Fang" last="Yeh">Ru-Fang Yeh</name></region><name sortKey="Dornan, David" sort="Dornan, David" uniqKey="Dornan D" first="David" last="Dornan">David Dornan</name><name sortKey="Shi, Xiaoyan" sort="Shi, Xiaoyan" uniqKey="Shi X" first="Xiaoyan" last="Shi">Xiaoyan Shi</name><name sortKey="Stinson, Susanna Y" sort="Stinson, Susanna Y" uniqKey="Stinson S" first="Susanna Y" last="Stinson">Susanna Y. Stinson</name><name sortKey="Yu, Nancy" sort="Yu, Nancy" uniqKey="Yu N" first="Nancy" last="Yu">Nancy Yu</name></country><country name="Suisse"><noRegion><name sortKey="Duchateau Nguyen, Guillemette" sort="Duchateau Nguyen, Guillemette" uniqKey="Duchateau Nguyen G" first="Guillemette" last="Duchateau-Nguyen">Guillemette Duchateau-Nguyen</name></noRegion><name sortKey="Nguyen, Tri Quang" sort="Nguyen, Tri Quang" uniqKey="Nguyen T" first="Tri Quang" last="Nguyen">Tri Quang Nguyen</name><name sortKey="Palermo, Giuseppe" sort="Palermo, Giuseppe" uniqKey="Palermo G" first="Giuseppe" last="Palermo">Giuseppe Palermo</name><name sortKey="Wenger, Michael K" sort="Wenger, Michael K" uniqKey="Wenger M" first="Michael K" last="Wenger">Michael K. Wenger</name></country><country name="Pologne"><noRegion><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></noRegion><name sortKey="Dmoszynska, Anna" sort="Dmoszynska, Anna" uniqKey="Dmoszynska A" first="Anna" last="Dmoszynska">Anna Dmoszynska</name><name sortKey="Warzocha, Krzysztof" sort="Warzocha, Krzysztof" uniqKey="Warzocha K" first="Krzysztof" last="Warzocha">Krzysztof Warzocha</name></country><country name="Russie"><noRegion><name sortKey="Salogub, Galina N" sort="Salogub, Galina N" uniqKey="Salogub G" first="Galina N" last="Salogub">Galina N. Salogub</name></noRegion><name sortKey="Rossiev, Viktor A" sort="Rossiev, Viktor A" uniqKey="Rossiev V" first="Viktor A" last="Rossiev">Viktor A. Rossiev</name></country><country name="France"><region name="Pays de la Loire"><name sortKey="Solal Celigny, Philippe" sort="Solal Celigny, Philippe" uniqKey="Solal Celigny P" first="Philippe" last="Solal-Celigny">Philippe Solal-Celigny</name></region></country><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Loscertales, Javier" sort="Loscertales, Javier" uniqKey="Loscertales J" first="Javier" last="Loscertales">Javier Loscertales</name></region></country><country name="Australie"><noRegion><name sortKey="Catalano, John" sort="Catalano, John" uniqKey="Catalano J" first="John" last="Catalano">John Catalano</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Larratt, Loree" sort="Larratt, Loree" uniqKey="Larratt L" first="Loree" last="Larratt">Loree Larratt</name></noRegion><name sortKey="Bence Bruckler, Isabelle" sort="Bence Bruckler, Isabelle" uniqKey="Bence Bruckler I" first="Isabelle" last="Bence-Bruckler">Isabelle Bence-Bruckler</name></country><country name="Danemark"><region name="Hovedstaden"><name sortKey="Geisler, Christian H" sort="Geisler, Christian H" uniqKey="Geisler C" first="Christian H" last="Geisler">Christian H. Geisler</name></region></country><country name="Italie"><region name="Lombardie"><name sortKey="Montillo, Marco" sort="Montillo, Marco" uniqKey="Montillo M" first="Marco" last="Montillo">Marco Montillo</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003655 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003655 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24916506
|texte= PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24916506" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |